Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
MBII Stock Overview
Marrone Bio Innovations, Inc. discovers, develops, and sells biological products for crop protection, crop health, and crop nutrition.
Marrone Bio Innovations Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.09 |
52 Week High | US$1.70 |
52 Week Low | US$0.55 |
Beta | 0.36 |
1 Month Change | -3.54% |
3 Month Change | 0.93% |
1 Year Change | -34.34% |
3 Year Change | -23.24% |
5 Year Change | -12.10% |
Change since IPO | -92.07% |
Recent News & Updates
Shareholder Returns
MBII | US Chemicals | US Market | |
---|---|---|---|
7D | 12.7% | -0.09% | 1.6% |
1Y | -34.3% | -11.1% | -20.8% |
Return vs Industry: MBII underperformed the US Chemicals industry which returned -10% over the past year.
Return vs Market: MBII underperformed the US Market which returned -20.4% over the past year.
Price Volatility
MBII volatility | |
---|---|
MBII Average Weekly Movement | 11.9% |
Chemicals Industry Average Movement | 6.8% |
Market Average Movement | 8.1% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.2% |
Stable Share Price: MBII is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: MBII's weekly volatility (12%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2006 | 153 | Kevin Helash | https://www.marronebio.com |
Marrone Bio Innovations, Inc. discovers, develops, and sells biological products for crop protection, crop health, and crop nutrition. Its products include Emergen, Foramin, Foramin ST, Optima, Takla, Pacesetter, Ympact, UBP, and UBP ST for increasing crop health, yield, and quality; Grandevo, a bioinsecticide that controls sucking and chewing insects through feeding; Haven, a plant health product to reduce sun stress and dehydration; Jet-Ag and Jet-Oxide peroxyacetic acid sanitizers that prevent, suppress, eliminate, and control algae, fungi, and bacterial diseases in agriculture and horticultural industries; and Majestene, a bionematicide to control soil-dwelling nematodes and certain soil borne insects. The company also offers Regalia and Stargus, which protects against fungal and bacterial diseases and enhances yields/quality; Venerate, a bioinsecticide that controls chewing and sucking insects and mites; and Zelto, a bionematicide that protects turf, including golf course fairways and greens, and promotes turf health by enhancing plant and root health.
Marrone Bio Innovations Fundamentals Summary
MBII fundamental statistics | |
---|---|
Market Cap | US$198.79m |
Earnings (TTM) | -US$20.89m |
Revenue (TTM) | US$44.37m |
4.5x
P/S Ratio-9.5x
P/E RatioIs MBII overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MBII income statement (TTM) | |
---|---|
Revenue | US$44.37m |
Cost of Revenue | US$17.89m |
Gross Profit | US$26.48m |
Other Expenses | US$47.37m |
Earnings | -US$20.89m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -0.11 |
Gross Margin | 59.69% |
Net Profit Margin | -47.08% |
Debt/Equity Ratio | 139.3% |
How did MBII perform over the long term?
See historical performance and comparisonValuation
Is MBII undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MBII?
Other financial metrics that can be useful for relative valuation.
What is MBII's n/a Ratio? | |
---|---|
n/a Ratio | 0x |
n/a | n/a |
Market Cap | US$198.79m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 5.1x |
Enterprise Value/EBITDA | -14.2x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does MBII's PS Ratio compare to its peers?
MBII PS Ratio vs Peers |
---|
Company | PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 28.2x | ||
KNGW Kenongwo Group US | 108.1x | n/a | US$255.7m |
BIOX Bioceres Crop Solutions | 1.8x | 18.6% | US$545.9m |
AGFS AgroFresh Solutions | 0.5x | 9.3% | US$91.1m |
IPI Intrepid Potash | 2.4x | -9.9% | US$616.3m |
MBII Marrone Bio Innovations | 4.5x | 24.7% | US$198.8m |
Price-To-Sales vs Peers: MBII is good value based on its Price-To-Sales Ratio (4.5x) compared to the peer average (28.2x).
Price to Earnings Ratio vs Industry
How does MBII's PE Ratio compare vs other companies in the US Chemicals Industry?
Price-To-Sales vs Industry: MBII is expensive based on its Price-To-Sales Ratio (4.5x) compared to the US Chemicals industry average (1.3x)
Price to Sales Ratio vs Fair Ratio
What is MBII's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 4.5x |
Fair PS Ratio | 5.6x |
Price-To-Sales vs Fair Ratio: MBII is good value based on its Price-To-Sales Ratio (4.5x) compared to the estimated Fair Price-To-Sales Ratio (5.6x).
Share Price vs Fair Value
What is the Fair Price of MBII when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate MBII's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate MBII's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MBII's PEG Ratio to determine if it is good value.
Discover undervalued companies
Future Growth
How is Marrone Bio Innovations forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score
2/6Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
70.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MBII is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MBII is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MBII is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MBII's revenue (24.7% per year) is forecast to grow faster than the US market (8.3% per year).
High Growth Revenue: MBII's revenue (24.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MBII's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Past Performance
How has Marrone Bio Innovations performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
8.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MBII is currently unprofitable.
Growing Profit Margin: MBII is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MBII is unprofitable, but has reduced losses over the past 5 years at a rate of 8.4% per year.
Accelerating Growth: Unable to compare MBII's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MBII is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (30.2%).
Return on Equity
High ROE: MBII has a negative Return on Equity (-91.33%), as it is currently unprofitable.
Discover strong past performing companies
Financial Health
How is Marrone Bio Innovations's financial position?
Financial Health Score
2/6Financial Health Score 2/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: MBII's short term assets ($33.0M) do not cover its short term liabilities ($41.7M).
Long Term Liabilities: MBII's short term assets ($33.0M) exceed its long term liabilities ($11.6M).
Debt to Equity History and Analysis
Debt Level: MBII's net debt to equity ratio (98.4%) is considered high.
Reducing Debt: MBII had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MBII has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: MBII has less than a year of cash runway if free cash flow continues to grow at historical rates of 11.3% each year.
Discover healthy companies
Dividend
What is Marrone Bio Innovations's current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MBII's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MBII's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MBII's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MBII's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as MBII has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
4.5yrs
Average management tenure
CEO
Kevin Helash (56 yo)
1.83yrs
Tenure
US$416,642
Compensation
Mr. Kevin R. Helash serves as Chief Executive Officer and Director at Marrone Bio Innovations, Inc. since August 03, 2020. He had been the Chief Executive Officer of Agrinos AS since November 20, 2017 unti...
CEO Compensation Analysis
Compensation vs Market: Kevin's total compensation ($USD416.64K) is below average for companies of similar size in the US market ($USD1.76M).
Compensation vs Earnings: Kevin's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: MBII's management team is considered experienced (4.5 years average tenure).
Board Members
Experienced Board: MBII's board of directors are considered experienced (4 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4%.
Top Shareholders
Company Information
Marrone Bio Innovations, Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: Marrone Bio Innovations, Inc.
- Ticker: MBII
- Exchange: NasdaqCM
- Founded: 2006
- Industry: Fertilizers and Agricultural Chemicals
- Sector: Materials
- Implied Market Cap: US$198.792m
- Shares outstanding: 182.38m
- Website: https://www.marronebio.com
Number of Employees
Location
- Marrone Bio Innovations, Inc.
- 7780-420 Brier Creek Parkway
- Raleigh
- North Carolina
- 27617
- United States
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/06/29 00:00 |
End of Day Share Price | 2022/06/29 00:00 |
Earnings | 2022/03/31 |
Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.